Assessment of platelet‐derived thrombogenicity with the total thrombus‐formation analysis system in coronary artery disease patients receiving antiplatelet therapy
Yuichiro Arima(Kumamoto University), Hisao Ogawa(Jikei University School of Medicine), Kenichi Tsujita(British Heart Foundation), Kenji Sakamoto(Kumamoto University), Miwa Ito(Kumamoto University), Daisuke Sueta(Mie University), Yu Oimatsu(Kumamoto University), Seiji Hokimoto(Omuta hospital), Sunao Kojima(Kumamoto University), Masanobu Ishii(Kumamoto University), Koichi Kaikita(Kumamoto University), Kazuko Nakagawa(Kumamoto University)
Cited by 55
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449